Metabolic Maintenance® L-Methylfolate 10 mg

Advanced active folate to support healthy mood, methylation, and cardiovascular function.*

What It Does
This higher-potency 10 mg dose of L-Methylfolate delivers robust support for mood and emotional well-being by supplying the active methyl donor required for healthy serotonin, dopamine, and norepinephrine pathways.* As the body’s bioactive folate form, it bypasses MTHFR-related conversion limitations to promote optimal neurotransmitter synthesis, homocysteine metabolism, and cellular energy production.* It also supports cardiovascular health, metabolic function, and balanced methylation throughout the body.*

How It Works
• L-Methylfolate (10 mg) — Provides a clinically relevant dose of the active folate required for methylation and one-carbon metabolic pathways.* [1]
• Optimizes Neurotransmitter Production — Supplies essential methyl groups for serotonin, dopamine, and norepinephrine synthesis to support balanced mood, emotional resilience, and cognitive function.* [2][3]
• Supports Homocysteine Balance — Promotes the conversion of homocysteine to methionine, helping maintain cardiovascular health and normal endothelial function.* [1][4][5]
• Enhances Energy and Metabolic Efficiency — Contributes to red blood cell formation and mitochondrial activity for steady energy, healthy metabolism, and overall vitality.* [6][7]

Who It’s For
Designed for individuals seeking elevated, bioactive folate support specifically for mood balance, neurological well-being, and methylation optimization.* Particularly suited for those with MTHFR polymorphisms, homocysteine-related concerns, or increased methylation demands from stress, lifestyle, or environmental exposures.*

Special Features
Features L-5-Methylfolate—the biologically active, clinically validated form of folate known for superior absorption and bioavailability. Manufactured to rigorous purity standards and free from common allergens.

References
1. Carboni L, et al. Integr Med (Encinitas). 2022;21(3):36.
2. Shelton RC, et al. Prim Care Companion CNS Disord. 2013;15(4).
3. Maruf AA, et al. Pharmacopsychiatry. 2021;55(03):139–47.
4. Antoniades C, et al. Circulation. 2006;114(11):1193–1201.
5. Willems FF, et al. Br J Pharmacol. 2004;141(5):825–30.
6. Hanna M, et al. Permanente J. 2022;26(2):89–97.
7. Xiu Y, Field MS. Curr Dev Nutr. 2020;4(10):nzaa153.